Channel Therapeutics

Channel Therapeutics is a preclinical biotech targeting the urgent need for non-opioid pain management. The company's core asset is a patented, potent, and selective inhibitor of the human NaV1.7 sodium channel, which has shown efficacy in multiple preclinical pain models. Its strategy is to pursue orphan drug designations for rare pain conditions like Erythromelalgia and Idiopathic Small Fiber Neuropathy to accelerate development, while also exploring broader applications in eye pain and other indications. The company is private and pre-revenue, seeking investment to advance its lead compound toward clinical trials.

Development of selective, potent small molecule inhibitors targeting the NaV1.7 voltage-gated sodium channel for non-opioid pain relief.

Channel operates in the competitive NaV1.7 inhibitor space, where several large pharma and biotech companies have faced clinical setbacks. Its initial focus on rare diseases is a differentiating strategy to avoid direct early competition with larger players in broad pain indications, though it may still face emerging competitors in the orphan pain niche.